Earnings shock and controversy over Corey investment review shake leadership of Hanmi Pharm CEO Hwang Sang-yeon
Predicted impact: Medium
Earnings shock and profit decline in Q3; leadership controversy adds some uncertainty to the stock.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.